KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Globus Medical (GMED) Raw Materials (2018 - 2025)

Globus Medical's Raw Materials history spans 8 years, with the latest figure at $152.1 million for Q3 2025.

  • For Q3 2025, Raw Materials rose 31.33% year-over-year to $152.1 million; the TTM value through Sep 2025 reached $152.1 million, up 31.33%, while the annual FY2024 figure was $122.0 million, 18.03% up from the prior year.
  • Raw Materials reached $152.1 million in Q3 2025 per GMED's latest filing, down from $153.3 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $153.3 million in Q2 2025 to a low of $41.7 million in Q1 2021.
  • Average Raw Materials over 5 years is $84.8 million, with a median of $75.0 million recorded in 2023.
  • Peak YoY movement for Raw Materials: rose 5.48% in 2021, then soared 71.32% in 2023.
  • A 5-year view of Raw Materials shows it stood at $41.8 million in 2021, then skyrocketed by 44.25% to $60.3 million in 2022, then skyrocketed by 71.32% to $103.3 million in 2023, then grew by 18.03% to $122.0 million in 2024, then grew by 24.71% to $152.1 million in 2025.
  • Per Business Quant, the three most recent readings for GMED's Raw Materials are $152.1 million (Q3 2025), $153.3 million (Q2 2025), and $118.6 million (Q1 2025).